Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) EBIT: 2010-2025

Historic EBIT for ProPhase Labs (PRPH) over the last 16 years, with Sep 2025 value amounting to -$4.8 million.

  • ProPhase Labs' EBIT rose 26.48% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.6 million, marking a year-over-year increase of 8.32%. This contributed to the annual value of -$38.6 million for FY2024, which is 82.04% down from last year.
  • ProPhase Labs' EBIT amounted to -$4.8 million in Q3 2025, which was down 22.34% from -$3.9 million recorded in Q2 2025.
  • ProPhase Labs' EBIT's 5-year high stood at $16.1 million during Q1 2022, with a 5-year trough of -$17.3 million in Q4 2024.
  • Moreover, its 3-year median value for EBIT was -$6.5 million (2023), whereas its average is -$6.6 million.
  • Within the past 5 years, the most significant YoY rise in ProPhase Labs' EBIT was 1,897.24% (2021), while the steepest drop was 2,557.63% (2021).
  • ProPhase Labs' EBIT (Quarterly) stood at $13.7 million in 2021, then slumped by 137.22% to -$5.1 million in 2022, then plummeted by 115.30% to -$11.0 million in 2023, then crashed by 57.77% to -$17.3 million in 2024, then climbed by 26.48% to -$4.8 million in 2025.
  • Its EBIT was -$4.8 million in Q3 2025, compared to -$3.9 million in Q2 2025 and -$3.7 million in Q1 2025.